{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:09:05Z","timestamp":1788952145055,"version":"build-2803163510"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Background<\/jats:title>\n The latest changes in racial and geographical enrollment in cancer clinical trials in the 2020s have not been fully characterized, despite ongoing measures by the US Food and Drug Administration (FDA) to enhance diversity. We aimed to quantitatively elucidate the trial population of FDA-approved cancer drugs by race and trial region in 2013\u20132024.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n FDA drug approvals granted from January 2013 through December 2024 were reviewed by the FDA Oncology (Cancer)\/Hematologic Malignancies Approval Notifications and FDA Application Review Files. Of 515 approval notifications screened, 92 eligible ones were analyzed. The primary endpoint was the ratio of each race and trial region among the datasets submitted for FDA approval.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Our analysis included 23,539 participants. Although the majority race has remained White, the proportion of White decreased from 83.2% in 2013\u20132016 to 68.9% in 2021\u20132024. The proportion of Asians and Asian trial region increased from 9.3% and 7.4% in 2013\u20132016 to 21.4% (95% CI, 20.53\u201322.35) and 19.7% (95% CI, 18.81\u201320.57) in 2021\u20132024, respectively. The proportion of Black people remained under 4%.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n From 2013 to 2016 to 2021\u20132024, Black people underrepresentation has persisted, whereas the enrollment of Asians at race level and participants from Asia at region level have increased.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1894533","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:34Z","timestamp":1788948754000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Race and trial region changes in cancer clinical trials between 2013 and 2024"],"prefix":"10.3389","volume":"13","author":[{"given":"Satoshi","family":"Hirano","sequence":"first","affiliation":[{"name":"Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Hanada","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Faculty of Medicine, Wakayama Medical University","place":["Wakayama, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"B2","year":"2016"},{"key":"B3","year":"2020"},{"key":"B4","year":"2020"},{"key":"B5","volume-title":"Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups","year":"2022"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e191870","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"key":"B7","volume-title":"Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Draft Guidance for Industry","year":"2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/picr.PICR_109_18","article-title":"Clinical trials in Asia: a World Health Organization database study","volume":"10","author":"Ali","year":"2019","journal-title":"Perspect. Clin. Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"B10","year":"2025"},{"key":"B11","year":"2025"},{"key":"B12","doi-asserted-by":"publisher","first-page":"110.e1","DOI":"10.1016\/j.ajog.2025.01.026","article-title":"Racial and ethnic enrollment disparities in clinical trials leading to food and drug administration approvals for gynecologic malignancies","volume":"233","author":"Levin","year":"2025","journal-title":"Am. J. Obstet. Gynecol"},{"key":"B13","year":"2024"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American society of clinical oncology and association of community cancer centers joint research statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"111791","DOI":"10.1016\/j.jclinepi.2025.111791","article-title":"Registered clinical trial trends evolved differently in east Asia vs the United States during 2014\u20132023","volume":"183","author":"Lee","year":"2025","journal-title":"J Clin Epidemiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1017\/cts.2021.813","article-title":"Participation of rural patients in clinical trials at a multisite academic medical center","volume":"5","author":"Bharucha","year":"2021","journal-title":"J Clin Transl Sci"},{"key":"B17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(14)70029-4","article-title":"Challenges to effective cancer control in China, India, and Russia","volume":"15","author":"Goss","year":"2014","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10900-005-7280-5","article-title":"Understanding immigrant Chinese Americans' participation in cancer screening and clinical trials","volume":"30","author":"Lin","year":"2005","journal-title":"J. Community Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1756-5391.2011.01137.x","article-title":"Chinese clinical trial registry: mission, responsibility and operation","volume":"4","author":"Wu","year":"2011","journal-title":"J. Evid. Based Med"},{"key":"B20","year":"2023"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1894533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:12:35Z","timestamp":1788948755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1894533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":20,"alternative-id":["10.3389\/fmed.2026.1894533"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1894533","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"1894533"}}